Subject: Can we look forward to a brighter 2021?

INSIDE THIS NEWSLETTER

  • COVID-19 UKRI Grant
  • Series A Fundraising
  • Hello Tomorrow: Investor Day & Global Summit
  • Digital RESI: Pitch Competition
  • Ansys Partnership
  • Media Coverage: ADLIB Recruitment
  • New Team Members
  • Job Postings
  • Meet our employee
A Light at the End of the Tunnel?
Can we look forward to a brighter 2021?
2020 was without a doubt one of the most challenging years in a generation. We do not know what 2021 will bring – one year ago no one predicted how much the world would change in the new year just arriving. But we do know that COVID-19 vaccines will be available, that treatments will improve, and can perhaps dare to hope that life will return somewhat to the way it was before. Although the current vaccines are showing very promising results we still do not have reliable treatments for those who already have COVID-19. As many of you know, we have focussed our efforts on developing a treatment that removes IL-6 from the bloodstream. In recent studies it was shown that targeting IL-6 can improve outcomes. We are very pleased to report that we have been awarded a grant to test our approach in clinical studies next year. It was a nice early Christmas present!

We wish you a very Happy New Year from all of us here at MediSieve!

UKRI COVID-19 Grant
We have received a £1.6M COVID-19 grant from the UKRI to trial our IL-6 product in COVID-19 patients. For the past few months, we have been focussing exclusively on our IL-6 removal product in order to respond to the pandemic. IL-6 is an “inflammatory cytokine”, a signalling molecule produced by your immune system in response to an infection like COVID-19. In severe cases, an overproduction of IL-6 causes the immune system to overreact, which can cause organ damage and death. The removal of IL-6 from critical patients can prevent this overreaction and thereby improve outcomes. This phenomenon is similar to Sepsis, which we are also targeting with this product.
Read more about the grant
https://apply-for-innovation-funding.service.gov.uk/competition/740/overview
Series A Funding
We are looking for experienced institutional investors to participate in our Series A, which will support pivotal clinical trials for our anti-IL-6 Magnetic Blood Filtration products. Please get in touch to request more information and a company deck.
Get in touch to get more information: info@medisieve.co.uk
MediSieve Attending Digital Events
This November was busy on exciting digital events. We had a chance to connect with the vibrant deeptech community during Global Summit and Investor Days organised by Hello Tomorrow. Later in the month our CEO, Dr George Frodsham, presented our technology in the Pitching Challenge at Digital RESI.
Follow us to learn where to meet us: https://www.linkedin.com/company/medisieve-limited/

MediSieve Secures Partnership with CADFEM and Ansys
Over autumn we started working with CADFEM, a leading CAE provider that supplies both the Ansys software and excellent supporting services. This has been made possible via the Ansys Startup program which has enabled us to access market leading software at an affordable cost. Thanks to both teams for getting us up and running!
Learn more about the Startup program: https://www.ansys.com/about-ansys/startup-program
Interview: ADLIB Recruitment
MediSieve was featured in one of the recent editions of ADLIB Recruitment "Product | People | Potential" interview series. Our founder and CEO, George Frodsham, talked to ADLIB about the backstory of MediSieve: from the company's origin to the recruitment and research challenges. 
Learn more about MediSieve's story: https://www.adlib-recruitment.co.uk/blog/product-people-potential-our-chat-with-medisieve/

Meet Our New Team Members
Over the last two months MediSieve welcomed two new team members: Cristina Piñel Neparidze and Danny Gold. Cristina is a BsC in Medical Biosciences student at Imperial College London. During her 5-month internship at MediSieve she will be working on the sepsis project. Danny joined MediSieve as a Simulation Engineer and will be enabling the further development of our products by using his knowledge of Ansys Simulation Software and Medical Engineering.
Learn more and meet the rest of the team:
https://www.medisieve.com/About-Us/Team

MediSieve Is Hiring
We are still on the look out for new talent to join our fantastic team and help us bring our exciting blood filtration technology through clinical trials and into the market. We are looking for highly motivated, engaging and proactive people to join our team as Senior Product Biochemist, Product Development Scientist, Lab Technician, and Regulatory Affairs Manager.
Please send your CV and a cover letter explaining what you can bring to MediSieve to jobs@medisieve.co.uk.

MediSieve Faces 
MediSieve is working on creating a novel blood filtration technology that will be the first of its kind. But what truly sets us apart from other companies is our people. Meet the individuals who are transforming our dream of eliminating the burden of blood-borne diseases into reality:
William Twigger
Head of Engineering & Quality 
Nationality: British
Joined: November 2017

What are your responsibilities within MediSieve?
- My core responsibility is anything and everything Engineering. From fixing lab equipment to planning and validating scale-up manufacturing of our products. I also lead the development of our Quality Management System, ensuring our processes and products confirm to the required standards.

What originally drew you to MediSieve?
- I always wanted to work for a startup to have the opportunity to turn an idea into something that provides significant benefit to society. Working closely with an Inventor is very rewarding for an Engineer, and to join the company in the early stages meant having a lot of freedom to explore exciting ideas to achieve our goals. 

What do you like most about working here?
- The team. We are an awesome group of young, diverse, intelligent and enthusiastic people. I look forward to the 1 day a week I have in the office to catch up properly and have that office small talk (all at a safe 2m distance!).

How did the COVID-19 outbreak affect your personal and work life?
- During this time we have been very fortunate to be able to keep working and have human (not screen!) interaction. It’s been a very busy year but we’ve made significant progress and the future looks very exciting. I’ve also been lucky to have a personal project of renovating my home – it’s gone more slowly than I’d hoped but an Engineer in a garage with tools is a happy Engineer.

"Imagine a world where doctors are able to target and remove infected cells, pathogens, toxins, or even viruses directly from a patient’s bloodstream."
You may unsubscribe or change your contact details at any time.